Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

Although irinotecan 350 mg m(−2) is a standard option for relapsed/refractory advanced colorectal cancer, there is some evidence that suggests that a higher dose may be more effective, with acceptable tolerability, following 5-fluorouracil (5-FU). This study assessed the optimal dosing strategy for...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Cutsem, E, Dirix, L, Van Laethem, J-L, Van Belle, S, Borner, M, Gonzalez Baron, M, Roth, A, Morant, R, Joosens, E, Gruia, G, Sibaud, D, Bleiberg, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361950/
https://www.ncbi.nlm.nih.gov/pubmed/15756271
http://dx.doi.org/10.1038/sj.bjc.6602462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361950/
https://www.ncbi.nlm.nih.gov/pubmed/15756271
http://dx.doi.org/10.1038/sj.bjc.6602462

Ejemplares similares